An randomized comparative study of efficacy and safety between mirtazapine and duloxetine hydrochloride in patients with cancer
Not Applicable
- Conditions
- Majar depression in cancer patient
- Registration Number
- JPRN-UMIN000008768
- Lead Sponsor
- Fukuoka University Faculty of Medicine Department of Psychiarty
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Brain metastasis confirmed 2)Congnitive impairment 3)Under interferon therapy 4)Bipolar disorder 5)Convulsive disorder or history of convulsive disorder 6)Prior electroconvulsive therapy 7)Dysuria, glaucoma or treatment for elevated intraocular pressure 8)Administration of the monoamine oxidase (MAO) inhibitor within observation period(2 weeks) 9)Hypersensitivity to mirtazapine or duloxetine hydrochloride 10)Pregnancy or lactating woman, woman planning pregnancy 11)Substance or alcohol abuse 180 days prior to administration of investigational drug. 12)Patient ineligible to the study based on investigator's decision.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in HAM-D scores between pretreatment baseline and 6-week treatment
- Secondary Outcome Measures
Name Time Method Specific symptoms (pain and nausea) Adverse events